US FDA approves Leqembi® IQKLIK™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer's disease
(BIOA-B) STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA-B) partner Eisai announced today the U.S. Food and Drug Administration (FDA) has approved the Biologi...
18 days ago